McKesson Corporation vs ProShares UltraPro S&P500 — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while ProShares UltraPro S&P500 trades at $154.81 (market cap $5.55B). The key difference: McKesson Corporation is far larger — about 19.5× ProShares UltraPro S&P500's market cap, and McKesson Corporation pays a 0.4% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and ProShares UltraPro S&P500 for 29 Days on average.
| MCK | UPRO | |
|---|---|---|
Market Cap | $108.46B | $5.55B |
Volume | 712,607 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $995.69 | $157.66 |
52-Week Low | $725.17 | $89.29 |
Typical Hold Time | 74 Days | 29 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
UPRO trades at $155.21, down 0.77% for the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The stock faces resistance near $156-$160 with support at $151-$147. Recent news highlights S&P 500 valuation concerns and projected earnings growth slowdown from 35% in 2026 to 15% in 2027, creating mixed sentiment around leveraged ETF performance.
Outlook remains cautiously optimistic given the bullish technical setup, though leveraged nature amplifies risks from market volatility and earnings growth deceleration. Key opportunities include potential year-end rally patterns, while risks center on concentrated market exposure and macroeconomic headwinds affecting the underlying index performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →